Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, Pápai Z, Prager G, Stein A, André T, Argilés G, Cubillo A, Dahan L, Edeline J, Leger C, Cattan V, Fougeray R, Amellal N, Tabernero J. Bordonaro R, et al. Among authors: cattan v. ESMO Open. 2021 Oct;6(5):100270. doi: 10.1016/j.esmoop.2021.100270. Epub 2021 Sep 20. ESMO Open. 2021. PMID: 34547581 Free PMC article. Clinical Trial.
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S. Burbridge MF, et al. Among authors: cattan v. Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26. Mol Cancer Ther. 2013. PMID: 23804704
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA. Bertran-Alamillo J, et al. Among authors: cattan v. Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5. Nat Commun. 2019. PMID: 31000705 Free PMC article.
Pixantrone: novel mode of action and clinical readouts.
Minotti G, Han H, Cattan V, Egorov A, Bertoni F. Minotti G, et al. Among authors: cattan v. Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18. Expert Rev Hematol. 2018. PMID: 29912583 Review.
Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols.
López Andrés N, Tesse A, Regnault V, Louis H, Cattan V, Thornton SN, Labat C, Kakou A, Tual-Chalot S, Faure S, Challande P, Osborne-Pellegrin M, Martínez MC, Lacolley P, Andriantsitohaina R. López Andrés N, et al. Among authors: cattan v. PLoS One. 2012;7(7):e39235. doi: 10.1371/journal.pone.0039235. Epub 2012 Jul 10. PLoS One. 2012. PMID: 22808030 Free PMC article.
21 results